Hemoperfusion in the intensive care unit.

"Declarations Conflicts of interestZR declares he received grants from BBraun. SR declares he received grants from Baxter an BBraun. TR has received funding for lectures, and been consultant or advisory board member for AstraZeneca, BBraun, Baxter, bioMérieux, Contatti Medical (CytoSorbents), Eurofarma, Jafron, Life Pharma, and Nova Biomedical. RB has received unrestricted research grants to investigate drug clearance with hemoperfusion and payment for advisory committee work by Jafron Biomedical Co Ltd. CR has been receiving honoraria, grants for studies or has been part of the advisory board and speaker bureau of the following companies in the last 3 years: Astute medical, Aferetica, Astrazeneca, Asahi Medical, Biomerieux, Baxter, Cytosorbents, Fresenius Medical Care, GE, ESTOR, Jafron, Medica, Medtronic, Novartis, Toray. Conflicts of interest ZR declares he received grants from BBraun. SR declares he received grants from Baxter an BBraun. TR has received funding for lectures, and been consultant or advisory board member for AstraZeneca, BBraun, Baxter, bioMérieux, Contatti Medical (CytoSorbents), Eurofarma, Jafron, Life Pharma, and Nova Biomedical. RB has received unrestricted research grants to investigate drug clearance with hemoperfusion and payment for advisory committee work by Jafron Biomedical Co Ltd. CR has been receiving honoraria, grants for studies or has been part of the advisory board and speaker bureau of the following companies in the last 3 years: Astute medical, Aferetica, Astrazeneca, Asahi Medical, Biomerieux, Baxter, Cytosorbents, Fresenius Medical Care, GE, ESTOR, Jafron, Medica, Medtronic, Novartis, Toray."

"Funding Open access funding provided by Università degli Studi di Firenze within the CRUI-CARE Agreement."